Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case- Control (MCC) Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Palazuelos, Camilo
  • Morros, Rosa|||0000-0001-6752-8748
  • Aragonés, Nuria
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Jiménez Monleón, Jose J.
  • Ruiz Cerdá, José Luis
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Ruiz-Dominguez, José Manuel
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Pollán, Marina|||0000-0002-4328-1565
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Llorca, Javier|||0000-0001-8569-861X
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

  • Peremiquel-Trillas, Paula
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Martín-Bustamante, Mayte
  • Casabonne, Delphine
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Oliete-Canela, Anna
  • Diéguez-Rodríguez, Marta
  • Tusquets, Ignasi
  • Amiano, Pilar
  • Mengual, Lourdes
  • Ardanaz, Eva
  • Capelo, Rocío
  • Molina de la Torre, Antonio José
  • Salas Trejo, Dolores
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lope, Virginia
  • Jimenez-Moleon, José J.
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Azpiri, Mikel
  • Muñoz, Montse
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Aragonés, Nuria
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Alguacil, Juan|||0000-0003-2703-9725
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Costas, Laura
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tumour characteristics and survivorship in a cohort of breast cancer, the MCC-Spain study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos-Calderón, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Guevara, Marcela|||0000-0001-9242-6364
  • Molina de la Torre, Antonio José
  • Domingo, Laia|||0000-0003-4420-0891
  • Fernández-Ortiz, María|||0000-0003-0017-875X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Alguacil, Juan|||0000-0003-2703-9725
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Ibáñez, Josefa
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Diaz-Santos, Marian
  • Alonso, M. Henar
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Ardanaz, Eva
  • Molinuevo, Amaia
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dietary Constituents, Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Gutiérrez-Ruiz, Nuria
  • Aragonés, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela|||0000-0001-9242-6364
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Alguacil, Juan|||0000-0003-2703-9725
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Canseco Fernandez, Rosario
  • Castilla, Jesus|||0000-0002-6396-7265
  • Molinuevo, Amaia
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m 2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p -trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement among Mediterranean Diet Pattern Adherence Indexes, MCC-Spain Study

  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • González-Donquiles, Carmen
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Romaguera, Dora|||0000-0002-5762-8558
  • Castelló, Adela|||0000-0002-1308-9927
  • Molina de la Torre, Antonio José
  • Amiano, Pilar
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lozano-Lorca, Macarena|||0000-0001-5282-814X
  • Alguacil, Juan|||0000-0003-2703-9725
  • Peiró, Rosana|||0000-0003-1525-4030
  • Huerta, José María|||0000-0002-9637-3869
  • Gracia-Lavedan, Esther
  • Aragonés, Nuria
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Solans, Marta|||0000-0002-2397-0435
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
There are many different methods used to measure the degree of adherence to a Mediterranean diet (MD), limiting comparison and interpretation of their results. The concordance between different methodologies has been questioned and their evaluation recommended. The aim of this study was to evaluate the agreement among five indexes that measure adherence to a Mediterranean dietary pattern. The study population included healthy adults selected in the Multi-Case Control Spain (MCC-Spain) study recruited in 12 provinces. A total of 3640 controls were matched to cases by age and sex. To reach the aim, the following scores of adherence to a Mediterranean dietary pattern were calculated: Mediterranean diet score (MDS), alternative Mediterranean diet (aMED), relative Mediterranean diet (rMED), dietary score (DS) and literature-based adherence score (LBAS). The relative frequency of subjects with a high level of adherence to a MD varied from 22% (aMED index) to 37.2% (DS index). Similarly, a high variability was observed for the prevalence of a low level of MD: from 24% (rMED) to 38.4% (aMED). The correlation among MDS, aMED and rMED indexes was moderate, except for MDS and aMED with a high coefficient of correlation 0.75 (95% CI 0.74-0.77). The Cohen's Kappa coefficient among indexes showed a moderate-fair concordance, except for MDS and aMED with a 0.56 (95% CI 0.55-0.59) and 0.67 (95% CI 0.66-0.68) using linear and quadratic weighting, respectively. The existing MD adherence indexes measured the same, although they were based on different constructing algorithms and varied in the food groups included, leading to a different classification of subjects. Therefore, concordance between these indexes was moderate or low.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Palazuelos, Camilo
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Altzibar, Jone M.
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bayo-Calero, Juan
  • Tardón, Adonina|||0000-0001-5150-1209
  • Salas, Dolores|||0000-0003-0064-1222
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Morros, Rosa|||0000-0001-6752-8748
  • Rodriguez-Cundin, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer, The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • de Pedro, María
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Servitja, Sonia|||0000-0001-6988-4519
  • Morros, Rosa|||0000-0001-6752-8748
  • Amiano, Pilar
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Diaz-Santos, Marian
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Lope, Virginia
  • Gracia-Lavedan, Esther
  • Alonso, M. Henar
  • Michelena-Echeveste, Maria Jesus
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. The online version of this article (doi:10.1186/s12885-016-2692-4) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

  • Solans, Marta|||0000-0002-2397-0435
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Romaguera, Dora|||0000-0002-5762-8558
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gracia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • González Barca, Eva|||0000-0002-1323-1508
  • Banda, Esmeralda de la
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias|||0000-0001-9850-9793
  • Llorca, Javier|||0000-0001-8569-861X
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • Gimeno, Eva|||0000-0002-3534-6189
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Sanjose, Sílvia de
  • Amiano, Pilar
  • Casabonne, Delphine
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.